{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', 'Figure 2.', 'Study Randomization', 'Part 1 dosing:', 'Part 2 dosing:', 'Part 3 dosing:', 'Day 1 to Week 24 (Day 168)', 'Weeks 24 to 48', 'Weeks 48 to up to 144', '110 mg BCX7353 QD', '110 mg BCX7353 QD', '110 mg BCX7353 QD', 'until transitioned to', 'X 24 weeks (Group 1)', 'x 24 weeks (Group 1)', '150 mg', '150 mg BCX7353 QD', '150 mg BCX7353 QD', '150 mg BCX7353 QD', 'X 24 weeks (Group 2)', 'x 24 weeks (Group 2)', 'x up to 96 weeks', '1:1:1 ratio', '110 mg BCX7353 QD', '110 mg BCX7353 QD', 'until transitioned to', 'x 24 weeks (Group 3a)', '150 mg', 'Placebo QD x 24', '2nd randomization at', 'weeks (Group 3)', 'Week 24:1:1 ratio', '150 mg BCX7353 QD', '150 mg BCX7353 QD', 'x 24 weeks (Group 3b)', 'X up to 96 weeks', 'Abbreviations: QD = once daily.', '9.4.', 'Study Drug Administration and Treatment Compliance', 'Subjects will be instructed to take BCX7353 capsules orally QD at approximately the same time', 'each day through up to 144 weeks as follows:', 'Treatment Group 1 (110 mg QD):', 'Parts 1 and 2: two 55 mg capsules of BCX7353 QD X 48 weeks', 'Part 3: one 110 mg capsule of BCX7353 QD until the subject can be', 'transitioned to the 150 mg dose', 'Treatment Group 2 (150 mg QD):', 'Parts 1 and 2: two 75 mg capsules of BCX7353 QD X 48 weeks', 'Part 3: one 150 mg capsule of BCX7353 QD X up to 96 weeks', 'Treatment Group 3a:', 'Parts 1 and 2 (placebo in Part 1, 110 mg in Part 2): two capsules of placebo', 'QD X 24 weeks (Days 1 to 168) followed by two 55 mg capsules of', 'BCX7353 QD X 24 weeks (Days 169 to 337)', 'Part 3: one 110 mg capsule of BCX7353 QD until the subject can be', 'transitioned to the 150 mg dose.', 'Treatment Group 3b:', 'Parts 1 and 2 (placebo in Part 1, 150 mg in Part 2): two capsules of placebo', 'QD X 24 weeks (Days 1 to 168) followed by two 75 mg capsules of', 'BCX7353 QD X 24 weeks (Days 169 to 337)', 'Part 3: one 150 mg capsule of BCX7353 QD X up to 96 weeks', '49']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', 'Subjects will be instructed to take study drug at approximately the same time each day, with', 'whichever meal is typically the largest meal of the day, or up to 30 minutes after consuming that', 'meal. It is recommended that the study drug be administered with food to help minimize GI', 'effects. If GI-related symptoms are noted as an AE, the site should query the subject and record', 'whether the drug is being taken as instructed (ie, with a meal).', 'Day 1 for the purposes of analysis in Part 1 is defined as the day that subjects take their first dose', 'of study drug. If the first study drug administration is different than the day of the baseline visit,', 'subsequent visits will be calculated from the day of first dose (Day 1), rather than the day of the', 'baseline visit. Clinic administration of study drug during study visits is not required. Subjects', 'will take study drug in Part 1 beginning on Day 1 and will complete Part 1 dosing on Study', 'Day 168 (the day before the Week 24 visit). Subjects will take Part 2 active study drug no sooner', 'than the conclusion of the Week 24 visit on Study Day 169, after all other study procedures have', 'been completed. Subjects will take Part 3 unblinded active study drug no sooner than the', 'conclusion of the Week 48 visit.', 'Subjects will be instructed to maintain approximately the same daily dosing interval between', 'study drug doses. If a subject forgets to take the study drug at the correct time, the dose may be', 'taken later in the day; however, no more than 1 dose of BCX7353 should be taken on any', 'calendar day. The subject should resume their regular dosing schedule on the next day. Dosing', 'may not be split across a day.', 'Subjects will be instructed to record in their diary the time of day study drug was taken, and the', 'number of capsules of study drug taken.', 'With the exception of the Week 2 and 26 visits, subjects will be instructed to bring all drug kits', '(including both unused and used bottles) and diaries with them for each study visit.', 'Accountability and adherence will be reviewed at these visits.', 'During the conduct of the study, responsibility for kit supply and resupply may be transferred to', 'a specialty pharmacy selected by the Sponsor and subjects may receive study drug directly from', 'the specialty pharmacy. Detailed instructions will be provided at the time of implementation.', 'If a specialty pharmacy is used, specialty pharmacy staff may contact subjects directly to better', \"understand the subject experience with study drug during the subject's participation in the study.\", '9.5.', 'Study Drug Dose Modification', 'Dose reductions are not permitted. Study drug interruptions are discussed in Section 12.1.8.', \"Based on the results of the current study's Part 1 analysis of greater efficacy and no increase in\", 'safety or tolerability risk at the 150 mg dose vs. the 110 mg dose, all subjects will be transitioned', 'to the 150 mg dose of BCX7353 on or after their Week 48 visit, regardless of their initial or', 'Week 24 treatment allocation, or, for those initially on 110 mg, their satisfaction with this dose', 'level.', '9.6.', 'Study Drug (Investigational Medicinal Product) Accountability', 'Accountability of study drug dispensed and returned (as applicable) will be performed at Day 1', 'and at each study visit with the exception of the Week 2 visit and Week 26 visit. Returned study', '50']\n\n###\n\n", "completion": "END"}